Company ProfilePremium

Jiangsu Yifan Biotechnology Co., Ltd.

Company Profile Analysis

Ticker: 002019.SZ

ESOMAR 23 Corporate BadgeISO Certifications Badge
Jiangsu Yifan Biotechnology Co., Ltd. - Company showcase

Year Founded & Workforce

2000

4,098 Employees

Jiangsu Yifan Biotechnology Co., Ltd. logo

Jiangsu Yifan Biotechnology Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Jiangsu Yifan Biotechnology Co., Ltd. Overview

Yifan Pharmaceutical is a mid-cap Chinese pharmaceutical group in transition from a commodity-API and drug-promotion business toward an innovation-led, internationalised specialty pharma company. Its anchor asset is Ryzneuta®/亿立舒 (efbemalenograstim alfa, F-627), a self-developed, non-PEGylated long-acting G-CSF. Ryzneuta is approved in 39 countries or regions including China, the US and the EU, and it is the only Chinese-originated long-acting G-CSF recommended in the NCCN hematopoietic growth factor guidelines.

Around this asset the company has assembled three further businesses:

  • A portfolio of exclusive and NRDL-listed traditional Chinese medicines (TCM), including Compound Huangdai tablets, which is on the WHO Essential Medicines List.

  • Niche injectable and oral chemical drugs, plus imported specialty products such as Xeloda® and Hyruan ONE®.

  • A legacy synthetic-biology and vitamin B5 (D-calcium pantothenate) franchise in which it holds a leading global share.

About 85% of revenue is drug-related. Overseas formulation revenue, licensing (Acrotech in the US) and a new in-licensing strategy (ACT001) form its growth narrative. Domestic volume-based procurement and TCM headwinds weigh on near-term growth.


Company's own description (FY2025 annual report abstract, translated)

During the reporting period the company was principally engaged in the research and development, production and sale of pharmaceutical products, active pharmaceutical ingredients (APIs) and polymer materials, and in drug-promotion services. Under the CSRC industry classification it belongs to pharmaceutical manufacturing. Its pharmaceutical products comprise biologics, chemical drugs and Chinese patent medicines. Its vitamin products are mainly vitamin B5 and pro-vitamin B5 (FY2025 annual report abstract, cnstock, 24 April 2026).

Management organises the drug business into four capability domains:

  1. Large molecules (biologics), anchored by Ryzneuta.

  2. Small molecules (chemical drugs), positioned around a "small, sharp, special, fast-to-revenue" niche strategy.

  3. Chinese patent medicines (TCM): 108 approval numbers, including 14 exclusive NRDL products.

  4. Synthetic biology: vitamin B5, pro-B5 and HMOs (human milk oligosaccharides).

Business and revenue model

Revenue typeDescriptionApprox. weight (FY2025)
Own pharmaceutical products (including imported and exclusively distributed products)Branded biologics, chemical drugs and TCM, sold through distributors to hospitals and retail, and abroad through partners and own registrations74.75% of revenue (RMB 3,837M)
Vitamins (B5 / pro-B5)Mostly direct B2B sales to feed, pharma, food and cosmetic customers. About 70% is exported to Europe, the Americas and other markets.11.95% (RMB 613M)
Other pharma revenue (promotion services, third-party products, milestones)Includes Ryzneuta sales milestones from domestic partners and residual CSO-type promotion revenueResidual of the pharma total of RMB 4,358M, i.e. about RMB 521M
Polymer materials and otherPVB (including photovoltaic-grade), PBS biodegradables, otherAbout RMB 162M (derived residual)

The licensing and milestone component matters at the margin. In China, Ryzneuta is commercialised with domestic partners: the company "recognised sales milestones" in 2024 from which more than RMB 500M of 2024 terminal net sales was inferred. In the US, Ryzneuta is out-licensed to Acrotech Biopharma, an Aurobindo subsidiary, under a supply-and-license model in which Evive manufactures and supplies and Acrotech commercialises.

Value-chain position and customers

The company is vertically integrated across the value chain:

  • API and biologic drug-substance manufacturing, including Beijing biologics drug substance and EU/US-GMP sterile fill lines.

  • Formulation.

  • Registration across more than 50 markets.

  • Commercial promotion through domestic medical-promotion teams and South-East Asia registration and sales teams.

Customer types:

  • Pharmaceutical distributors and hospital channels in China.

  • Retail pharmacy for OTC TCM.

  • Overseas licensees and distributors.

  • B2B buyers of vitamin B5 and polymers.

End-markets:

  • Oncology supportive care (chemotherapy-induced neutropenia).

  • Haematologic oncology (APL).

  • Orthopaedics (knee osteoarthritis).

  • Dermatology, paediatrics and respiratory (TCM).

  • Critical care injectables.

  • Animal feed and nutrition (vitamin B5).

  • Photovoltaic and laminated glass (PVB).

Independent characterisation

Yifan is best understood as three businesses with very different economics:

  1. A single-asset innovative biologics franchise (Ryzneuta). High gross margin, globally registered, but still commercially early overseas. Management concedes it "has not yet contributed profit at scale" (FY2025 annual report abstract).

  2. A cash-generative but policy-exposed domestic specialty-generics and TCM portfolio. Exposed to volume-based procurement (VBP), DRG/DIP payment reform and hospital-sales compression, which drove the H1 2026 decline.

  3. A cyclical commodity vitamin B5 business. Global leadership, but price-taker economics. This segment caused the 2021 earnings collapse (vitamin B5 revenue -61% in 2021).

The investment case rests on whether (1) and new in-licensed or clinical assets (ACT001, F-652, N-3C01) can outgrow the erosion in (2) and the cyclicality of (3).

Strategy

Stated strategy (annual and interim reports)

  • Medium- to long-term plan: "innovation + internationalisation" (创新、国际化). The company commits to a "long-termist, safe, controllable, sustainable development philosophy" (H1 2025 report).

2025 operating theme: "Meet the challenge, respond to the challenge, win the challenge" (迎战、应战、赢战).

"Big product" cluster strategy (set for 2024): - Overseas: 2 products above RMB 100M and 4 above RMB 50M.

  • Domestic: 9 products above RMB 100M and 9 above RMB 50M.

  • In-license 8–10 new products around Ryzneuta for APAC and emerging markets.

  • First synthetic-biology product ready for trial production by end-2024.

Globalisation model: "licensing partnerships plus own registrations" across more than 50 markets, with the stated aim of moving from "product going abroad" to "value going abroad", i.e. pricing power (company and press framing, 2025).

R&D focus: differentiated innovation concentrated on a few large-molecule assets (G-CSF, IL-22), plus biosimilars with "head-generic" potential.

FY2026 plan (FY2025 annual report)

  • Advance:

    • N-3C01 China–Australia Phase I;

    • F-652 healthy-volunteer PK and the China Phase II in aGVHD;

    • tracking of the F-652 US IIT;

    • human growth hormone clinical trials;

    • ACT001 clinical progress and risk control;

    • Compound Yinhua Jiedu supplementary studies per CDE.

  • Lay out at least one best-in-class (BIC)-potential frontier target.

  • Initiate one or two biosimilars with head-generic potential.

  • Adopt a "Quality and Return Dual Improvement" (质量回报双提升) action plan (board, 22 Apr 2026), in line with CSRC market-value-management guidance.

Initiatives in the last 24 months

DateInitiativeType
2024–2025Transfer of Ryzneuta US/EU MAH to Evive entities; first-time US supply (delayed by packaging issues)Platform / supply chain
2,025HMO portfolio (2'-FL FDA, 6'-SL self-GRAS); new Hangzhou synthetic-biology plantNew business launch
2,025PIC/S inspection (norepinephrine); EU certification (amikacin)International quality platform
2,025Oxytocin nasal spray licensed to Sygardis Rus (Russia)Out-licensing
Jan 2026ACT001 in-licence (RMB 100M upfront)Business development
H1 2026New Ryzneuta commercial partnerships in France, Italy, Poland and Bangladesh; EMA approval of an additional overseas formulation site; shelf-life extensionsCommercial / supply
Apr 2026Quality and Return Dual Improvement plan; new remuneration system; FY2025 Sustainability ReportGovernance / ESG
Sep 2026RMB 100M LP commitment to the Gaorong Changying fund (RMB 3.35bn target), focused on emerging industriesStrategic investment

Guidance

The company does not issue formal numerical guidance. Its budget commentary for vitamins ("basically in line with the beginning-of-year budget target") and its product-count ambitions are the closest equivalents. No medium-term revenue or margin targets were found.

Products & Services

Prices are not disclosed unless stated. "NRDL" means China National Reimbursement Drug List.

Large molecules (biologics)

ProductDescription and capabilitiesTarget customerApproval / launchCommercial model / price
Ryzneuta® / 亿立舒 (efbemalenograstim alfa, F-627)Novel dimeric G-CSF Fc-fusion protein; long-acting without PEGylation; prevention of chemotherapy-induced neutropenia. The only G-CSF with head-to-head trials against both the long-acting and short-acting originators that met pre-set endpoints. Included in NCCN HGF guidelines (Category 1 in v3.2026; v1.2025 inclusion), the CSCO breast cancer guideline 2025 and the German S3 supportive-therapy guideline. Shelf life is 36 months in China and 48 months overseas (EU/FDA approved).Oncology centres; chemotherapy patientsChina 2023 (first shipments Jun 2023); US FDA Nov 2023; EU Mar 2024; 39 countries or regions by mid-2026China: partner model with sales milestones; NRDL since Dec 2023 (with a later price cut noted in H1 2026). US: licensed to Acrotech; launched Jul 2025 at USD 4,600 per vial, about 14x the China price. Europe and other markets: partners in France, Italy, Poland, Bangladesh and others.
F-652 (recombinant human IL-22-Fc fusion protein)First-in-class IL-22 agonist candidateHepatology and transplantClinical: China IND for ACLF (2021); China Phase II IND for acute GVHD (Jan 2026); higher-dose PK in healthy volunteers completed; US IIT ongoingPipeline
N-3C01 injectionInnovative biologic for advanced solid tumours and NMIBCOncologyIND cleared in 2025; China–Australia Phase I planned for 2026Pipeline
Insulin glargine injection; human growth hormone injectionBiosimilars / follow-on biologicsEndocrinologyClinical trial approvals received in 2025Pipeline
Third-generation insulins (three products)Biosimilars for overseas marketsDiabetesPre-clinical (2024)Pipeline
F-899Innovative biologic; China IND completed 2021Not detailedClinicalPipeline

Small molecules: chemical drugs (domestic)

ProductDescriptionTherapeutic areaNotes
Xeloda® (capecitabine tablets)Oral fluoropyrimidineOncologyImported or licensed brand; volume growth in 2025
Hyruan ONE® / 易尼康 (cross-linked sodium hyaluronate injection)Single-injection viscosupplement; LG Chem's SynovianKnee osteoarthritisExclusive import and distribution; China approval Apr 2023; NRDL Dec 2023; H1 2025 shipments +478%; FY2025 sales +224.72%
Emedastine difumarate extended-release capsulesAntihistamineAllergy / dermatology2025 volume growth
Puvanle® / 普帆乐 (plerixafor injection)Stem-cell mobiliserHaematology—
Oxytocin nasal sprayUterotonic / lactationObstetricsRussia rights licensed to Sygardis Rus (2025)
Vincristine sulfate injectionVinca alkaloidHaemato-oncology—
Norepinephrine bitartrate injectionVasopressorCritical carePIC/S inspection passed; Singapore approval Feb 2026
Phenylephrine hydrochloride injectionVasopressorCritical care—
Yifala® / 亿法拉 (clofarabine injection)Purine analoguePaediatric ALL—
Cytarabine for injection; epirubicin HCl for injectionCytotoxicsHaemato-oncologyRegistered H1 2025
Vitamin K1 injection (0.2ml:2mg; 1ml:10mg)CoagulationHospitalChina approval Jan 2026
Polymyxin B sulfate for injectionLast-line antibioticInfectious diseaseChina approval Jan 2026
Lactulose oral solutionLaxative / hepatic encephalopathyGIExclusive import or distribution
Amikacin sulfate injectionAminoglycosideInfectious diseaseEU certified; shipped to Italy (2025)
Diazoxide oral suspensionHyperinsulinismRare / paediatricEmergency export to Brazil (2025)

Small molecules: overseas

ProductMarketNotes
Zometa® (zoledronic acid for injection)Overseas, via the NovoTek / SciGen platformNamed overseas product (FY2025 annual report)
Imported and own formulationsSouth-East Asia, Singapore, EU (Italy)Via SciGen (Singapore) and Italian subsidiaries

Traditional Chinese medicines (108 approval numbers; 14 exclusive NRDL products)

ProductIndicationDistinction
Baixuekang® / 柏雪康 (Compound Huangdai tablets, 复方黄黛片)Acute promyelocytic leukaemia (APL)Second-class National Science & Technology Progress Award; mechanism published in leading international journals including NEJM; in Chinese APL guidelines and the ELN consensus; on the WHO Essential Medicines List. Brazil APL study and a platinum-resistant ovarian cancer IIT under way.
Xiao'er Qingqiao granules (小儿青翘颗粒)Paediatric respiratoryExclusive NRDL product; sharp decline in H1 2026
Compound Yinhua Jiedu granules (复方银花解毒颗粒)Influenza / respiratoryPhase III in paediatric influenza completed and filed; CDE supplementary data requested
Chushi Zhiyang ointment (除湿止痒软膏)Eczema / pruritusExported to Singapore (2025)
Pimingxiao capsules (皮敏消胶囊)Dermatology / urticariaExported to Singapore; 2025 volume growth
Fuyinkang lotion (妇阴康洗剂)GynaecologyExclusive
Maqin Xiaoke granules (麻芩消咳颗粒)CoughSingapore registration (second TCM registered overseas)
Ginkgo leaf pills (银杏叶丸)Cardio-cerebrovascularExported to Singapore
Yihuang decoction granules (易黄汤颗粒)Classical formulaNDA accepted Jan 2026 (Suzhou Yifan)
Duanjin Jiedu capsules (断金戒毒胶囊)Opioid-dependence relapse preventionClass 1.1 innovative TCM; Phase Ib completed (2025)

Synthetic biology and vitamins

ProductDescriptionMarket position
Vitamin B5 (D-calcium pantothenate) and pro-vitamin B5 (D-panthenol)Feed, pharma, food and cosmetic ingredients; direct sales; about 70% exportedGlobal leader by share; prices cyclical. Management cites industry oversupply in 2025.
HMOs: 2'-fucosyllactose (2'-FL) and 6'-sialyllactose (6'-SL)Infant-formula and nutrition ingredientsFDA (GRAS) clearance for 2'-FL and self-GRAS for 6'-SL (2025); new Hangzhou plant ramping up

Polymer materials

ProductDescription
Xinfu PVB resin and filmIncluding photovoltaic-grade PVB interlayer resin (investor-relations disclosure)
PBS fully biodegradable resinCapacity of 10,000 t (investor-relations reply, Jul 2020; current capacity not re-verified)

In-licensed pipeline

AssetLicensorTermsStatus
ACT001 (dimethylaminomicheliolide fumarate monohydrate)Tianjin Shangde Yaoyuan Technology and two subsidiariesExclusive, sublicensable rights for SCLC brain metastases in mainland China, Korea and several South-East Asian countries. RMB 100M upfront; cornerstone equity investment or milestones (alternative); tiered royalties on net sales.NMPA Breakthrough Therapy designation (Jan 2025). Phase III: 166 patients enrolled in H1 2026, 76% of target.

Financial Narrative

Basis and sources. All figures are PRC GAAP (CAS), consolidated, in RMB M, from audited annual reports:

  • FY2025: annual report abstract and cfi.cn.

  • FY2022–FY2024: FY2024 annual report key data.

  • FY2021: CS.com.cn summary of the FY2021 annual report.

Blank cells mean the figure was not disclosed in the sources reviewed. Computed ratios are marked (c).

Income statement

Notes:

  • FY2021 gross profit is computed (c) from the 41.47% gross margin.

  • FY2025 consolidated net profit is RMB 373.45M (Pharnexcloud). cfi.cn shows RMB 431.75M against minorities of RMB -28.57M, which is internally inconsistent (402.02 - 28.57 = 373.45). The RMB 373.45M figure is adopted.

  • Minorities are derived (c) as consolidated NP less attributable NP. Losses at Evive, 66.92% owned, explain the large FY2023 minority loss.

  • Dividends: FY2024 had an RMB 0.10 interim plus an RMB 0.10 final. Cumulative cash dividends for FY2023–FY2025 were RMB 364.9M, consistent with three payments of RMB 121.6M (FY2025 profit-distribution notice). The FY2021 dividend was nil (FY2021 annual report).

  • EBITDA: D&A was not captured in the sources reviewed, so EBITDA is not publicly disclosed here.

Margins and growth (%)

Revenue CAGR (c).

  • FY2021–FY2025: 3.9% per year (RMB 4,409M to RMB 5,133M).

  • FY2022–FY2025: 10.2% per year.

  • FY2020–FY2025: -1.0% per year, from the cyclical peak of RMB 5,401M.

Balance sheet

Notes:

  • FY2021 total assets and liabilities are computed (c) from RMB 8,535M of net assets and a 27.87% debt ratio.

  • FY2023 and FY2024 liabilities are computed (c) from the debt ratios reported by Radar Finance.

  • Cash and cash equivalents at year end were RMB 663.8M (FY2025), RMB 730.3M (Q1 2026) and RMB 809.5M (H1 2026) (cfi.cn).

  • Goodwill: the large FY2023 impairment reduced the FY2021 balance of RMB 2,738M (32% of net assets). The current balance is not captured.

  • Short-term and long-term borrowings, net debt and working capital are not captured in the sources reviewed (not publicly disclosed here). Contextual signals:

    • Stockstar notes cash covered only 33.63% of current liabilities at 3Q25.

    • The controlling shareholder personally guarantees up to RMB 3.0bn of bank borrowings.

    • Intra-group guarantees of up to RMB 6.0bn are authorised, equal to 67.92% of FY2025 net assets.

Cash flow

Capex and buybacks were not captured, so free cash flow is not publicly disclosed here. As a proxy, OCF plus investing cash flow was RMB +4M in FY2025. The company holds about 9.63M treasury shares from earlier buybacks. In H1 2026, OCF of RMB 593.5M was stronger than in H1 2025 (RMB 286.1M) on lower purchases and taxes and the timing of government grants.

Return and efficiency ratios

FY2025 ROE, ROA and asset turnover are computed (c). The following ratios are not publicly disclosed in the sources reviewed:

  • current ratio;

  • debt/equity (interest-bearing);

  • net debt/EBITDA;

  • interest coverage;

  • cash conversion cycle.

Liabilities/equity (total, not interest-bearing) was 0.47x in FY2025 (c).

Commentary on trends, inflections and drivers

FY2020–FY2021: commodity-cycle collapse. FY2020 was flattered by unusually high vitamin B5 prices. In FY2021, vitamin B5 revenue fell 61% to RMB 470M, API-segment gross margin fell by about 32 points, and promotion-service revenue fell 43% as partner products entered VBP. Group revenue fell 18% and attributable NP fell 71%. Management's response was to pivot toward own products: own-product revenue rose 25% in FY2021.

FY2022: margin repair, revenue down. Gross margin recovered to 48.6% as mix shifted toward own pharma products. Revenue still contracted 13% and profit stayed thin, with attributable NP of RMB 191M.

FY2023: kitchen-sink loss. Revenue grew 6% to RMB 4,068M and chemical-drug revenue rose 40.7%. Asset and goodwill impairments and an R&D expense ratio that rose 2.72 points to 7.68% nevertheless produced an attributable loss of RMB 551M and a consolidated loss of RMB 886M. The year reset the asset base: total assets fell about RMB 1.0bn.

FY2024: the inflection year. Revenue rose 26.8% to RMB 5,160M. Drivers were:

  • the first full year of NRDL-listed Ryzneuta and Hyruan ONE;

  • domestic own-product growth of 88% in H1 2024;

  • higher government grants and lower impairments.

Attributable NP returned to RMB 386M, OCF hit a five-year high of RMB 641M, and dividends resumed.

FY2025: quality over quantity. Revenue was flat (-0.5%). Pharma revenue grew 2.3% while vitamins fell about 15% in an oversupplied market. Gross margin dipped to 46.9% on lower vitamin pricing and own-product mix. Core profit improved materially: NP excluding non-recurring items rose 30.9%, helped by innovative-product revenue (Hyruan ONE +225%; Ryzneuta shipments +80%). Q3 2025 attributable NP nonetheless fell 25.6% YoY. The full-year result of RMB 402M was well below the roughly RMB 600M consensus at 3Q25 (Stockstar).

H1 2026: renewed pressure. Revenue fell 6.4% and attributable NP fell 32.5%. Causes were:

  • respiratory TCM declines;

  • the Ryzneuta NRDL price reduction;

  • higher R&D expense (ACT001 Phase III, F-652);

  • FX losses;

  • lower government grants.

The quality of earnings improved (non-recurring items were small) and OCF more than doubled.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment / product line (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Pharma own products incl. imported (CNY Mn)

1,627—2,4323,6643,837

Total pharma business (CNY Mn)

———4,2604,358

Vitamins B5 series (CNY Mn)

470——718613

API segment total, incl. vitamins (CNY Mn)

1,062————

Pharma promotion services (CNY Mn)

907————

Group revenue (CNY Mn)

4,4093,8374,0685,1605,133

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Gross margin (%)

Gross margin (%)FY2021FY2022FY2023FY2024FY2025

Pharma own products incl. imported (%)

61.84—57.0552.4651.88

Vitamins (%)

————41.66

API segment, incl. vitamins (%)

44.54————

Pharma services (%)

25.62————

Group gross margin (%)

41.4748.6347.8447.4246.88

Share of group revenue (%)

Share of group revenue (%)FY2021FY2023FY2024FY2025

Pharma own products (%)

36.9059.7971.0274.75

Vitamins (%)

10.66—13.9211.95

Pharma services (%)

20.57———

YoY growth (%)

YoY growth (%)FY2021FY2022FY2023FY2024FY2025

Pharma own products (%)

25.08——50.664.71

Vitamins B5 (%)

-61.37———-14.62

Group revenue (%)

-18.36-12.986.0326.84-0.52

Revenue by Segment (Half-Yearly)

H1 metric (CNY Mn)H1 2025H1 2026

Group revenue

2,6352,468

Pharma total

2,2542,029

Pharma own products incl. imported

1,9901,837

Vitamins

302—

Group Entities

EntityOwnershipRole

Hefei Yifan Biopharmaceutical (亿帆生物)

100%

Pharma holding and commercial platform

Hefei Yifan Pharmaceutical (合肥亿帆)

100%

Pharma commercial

Hefei Yifan Bio-Pharmaceutical Manufacturing (亿帆制药)

100%

Formulation manufacturing; licensee of ACT001

Sichuan Defeng, Tianchang Yifan, Liaoning Yifan, Suzhou Yifan, Hunan Furong, Shenyang Aohua

100% via Yifan Pharma

TCM and chemical formulation plants

Sichuan Kaijing Pharma

51%

Formulations

Beijing Jisheng Kangtai

71%

Pharma technology

Yifan Youshengmeite

51%

Pharma technology

Hefei Xinzhu Biotech

100%

Biologics/formulation; EU QP-audited; investment vehicle for the Gaorong fund

Evive Biotech Ltd. (Cayman)

66.92% via HK Yifan

Large-molecule innovation; subsidiaries in Shanghai, Beijing, HK, US (Delaware), Singapore and Ireland

Hangzhou Xinfu Technology, Anqing Xinfu, Chongqing Xinfu, Huzhou Xinfu New Materials, Zhejiang Yiben Tech

100%

Vitamin B5, pro-B5 and polymers (PVB, PBS)

Yifan International (HK), NovoTek Pharmaceuticals (HK), Feisuo Medicine and Tek Medicine (Italy), SciGen Pte Ltd (Singapore), YF Pharmaceutical International (US), YiFan Pharma (US)

100%

International registration and commercial platform

Yifan Pharmaceutical Research Institute (Beijing)

100%

Central R&D

Bioton S.A. (Warsaw Stock Exchange)

31.65%, indirect

Associate; Polish insulin producer

ITabMed Co., Ltd.

15.64% via Evive

Minority biotech investment

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

4,4093,8374,0685,1605,133

Gross profit (CNY Mn)

1,8281,8661,9462,4472,406

Operating profit (CNY Mn)

————429

Total profit before tax (CNY Mn)

————424

Net profit, consolidated (CNY Mn)

—127-886324373

Net profit attributable to parent (CNY Mn)

278191-551386402

Net profit attributable, excl. non-recurring items (CNY Mn)

22090-533248325

Minority interests (CNY Mn)

—-64-335-62-29

Basic EPS (MYR Bn)

0.230.16-0.450.320.33

Diluted EPS (MYR Bn)

—0.15-0.450.320.33

Dividend per share (MYR Bn)

0000.200.10

Margin Analysis (%)

Metric (%)FY2021FY2022FY2023FY2024FY2025

Gross margin (%)

41.4748.6347.8447.4246.88

Operating margin (%)

————8.35

Net margin, attributable (%)

6.314.98-13.557.487.83

Net margin, consolidated (%)

5.493.31-21.776.277.28

Revenue growth YoY (%)

-18.36-12.986.0326.84-0.52

Attributable NP growth YoY (%)

-71.25-31.22-388.19170.044.16

Balance Sheet and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (CNY Mn)

11,83312,54411,50012,28612,845

Total liabilities (CNY Mn)

3,298—3,2453,8594,134

Equity attributable to parent (CNY Mn)

—8,8128,2768,5228,835

Total equity (CNY Mn)

8,535———8,711

Cash and cash equivalents at year end (CNY Mn)

————664

Goodwill (CNY Mn)

2,738————

Liabilities-to-assets ratio (%)

27.87—28.2231.4132.18

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (CNY Mn)

301472349641458

Investing cash flow (CNY Mn)

-508———-454

Financing cash flow (CNY Mn)

222———-114

Dividends declared for the year (CNY Mn)

000243122

OCF / attributable NP (x)

1.082.47—1.661.14

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, weighted average (%)

3.282.20-6.354.484.63

ROIC (%)

2.44————

ROA (%)

————2.97

Total asset turnover (x)

0.37———0.41

Receivables turnover (x)

4.23————

Inventory turnover (x)

4.14————

Cash Flow

Metric (CNY Mn)Q1 2025Q1 2026H1 2025H1 2026

Revenue

1,3271,2562,6352,468

Attributable NP

153107304205

Attributable NP excl. non-recurring

95104237203

Operating cash flow

182285286594

Geographic Indicator Details

Geographic indicatorDetailSource

Overseas formulation revenue

"Record high" in H1 2024; an H1 2025 figure exists in the investor-relations Q&A but was truncated in the source

STCN Aug 2024; Stockstar

Vitamin B5 export share

About 70% sold to Europe, the Americas and other regions

FY2025 annual report abstract

Markets with product sales

More than 50 countries or regions cumulatively

FY2025 annual report abstract

Ryzneuta approvals

31 (Aug 2024), 36 (end-2025), 39 (mid-2026)

STCN; FY2025 annual report; Tianfeng

Ryzneuta US end-price

USD 4,600 per vial, about 14x the China price

ifeng; Fxbaogao investor-relations minutes

Acrotech US order

Binding 2025 purchase orders above 40k vials (half-year); volume and sales targets raised in May 2025

CLS, Aug 2025

Geographic revenue (CNY Mn)

FY2023

FY2024

Segment Overview

SegmentChinaUSEuropeSouth-East Asia / SingaporeLatin AmericaOther

Ryzneuta (biologics)

Core volume via partners; NRDL

Acrotech license; launched Jul 2025

EU approved Mar 2024; partners in Germany, France, Italy, Poland, UK

Registrations

Brazil approved

Russia, Bangladesh and the Balkans (Albania, Kosovo, Montenegro)

Chemical drugs

VBP-exposed; specialty niches

US subsidiaries

Italy (Feisuo/Tek); amikacin to the EU

Singapore (SciGen); norepinephrine approved

Diazoxide to Brazil

Oxytocin nasal spray to Russia

TCM

Core market

——

Singapore exports of four products

Brazil APL trial (Huangdai)

—

Vitamin B5

About 30%

Major export destination

Major export destination

———

Share Price History

DatePrice (MYR Bn)Context

30 Sep 2025

13.74

Northbound snapshot

31 Dec 2025

11.84—

31 Mar 2026

12.56—

30 Jun 2026

9.35—

30 Jul 2026

10.23

Market cap RMB 12.44bn; float market cap RMB 8.61bn

31 Jul 2026

10.27

Latest captured

Valuation Multiples

MultipleYifanPeer reference (Shenwan chemical-API median)

P/E (TTM)

35.0x

52–53x

P/E historical percentile

About 5–6% (near the low of its own history; minimum 31.98x)

—

P/B

1.42x2.5x

Dividend yield

About 0.98%

About 1.05%

EV/Sales (c)

About 2.4x (market cap / FY2025 revenue; excludes net debt, which was not captured)

—

EV/EBITDA

Not publicly disclosed (EBITDA not captured)

—

Analyst Ratings & Targets

BrokerDateRatingForecasts

Tianfeng Securities (Yang Song, Cao Wenqing)

Sep 2026

Buy (maintained)

Revenue: RMB 5,189M (2026E), 5,555M (2027E), 5,940M (2028E). Attributable NP: RMB 431M, 533M, 659M.

Zheshang Securities

10 Sep 2026

Upgraded to Buy

Not captured

Guosheng Securities

2024

Buy

FY2024–26 NP of RMB 574M / 727M / 943M (since overtaken by actuals: FY2024 RMB 386M, FY2025 RMB 402M)

Consensus (Stockstar, 3Q25)

Oct 2025

—

FY2025 NP of RMB 600M and EPS of RMB 0.49 (actual RMB 402M and RMB 0.33, a miss)

Forecast metric (Tianfeng, Sep 2026)

FY2026

FY2027

FY2028

Revenue (CNY Mn)

5,1895,5555,940

Attributable NP (CNY Mn)

431533659

Analyst Conclusions

Guidance and consensus

The company gives no numerical guidance. Tianfeng's September 2026 model implies:

  • FY2026 revenue of about RMB 5.19bn, roughly flat (+1.1%);

  • FY2026 attributable NP of RMB 431M (+7%);

  • an acceleration to RMB 659M by FY2028, a 2025–2028 CAGR of about 18%.

Hitting FY2026 requires a strong H2: H1 NP was only RMB 205M, so H2 needs about RMB 226M, against RMB 98M in H2 2025.

Bull case

  1. Ryzneuta becomes a genuine global product. Shipments rose more than 80% in 2025 and more than 50% in H1 2026, approvals reached 39 countries, and NCCN Category 1 status plus a USD 4,600 US price give it a long runway. A second EMA-approved site removes the supply bottleneck.

  2. ACT001 delivers a first-in-indication approval. Phase III is 76% enrolled with BTD, which could deliver a 2027–2028 launch into an unmet SCLC brain-metastases niche for an upfront of only RMB 100M.

  3. Valuation is near historical lows. P/E of about 35x sits at the 5th–6th percentile of its own history and P/B of 1.4x against a sector of 2.5x. Improving core profit (+31% in FY2025) and strong OCF in H1 2026 suggest de-risked downside.

Bear case

  1. The domestic base is eroding faster than innovation grows. Own products fell 7.7% in H1 2026, respiratory TCM declined steeply, and the Ryzneuta NRDL price cut means two innovative products grew revenue only 12.5% despite 40% higher shipments.

  2. The profit record is undermined by misses. FY2025 NP was a third below consensus, Q1 and H1 2026 NP fell about 30%, and grant dependence and FX make earnings noisy. Single-digit ROE does not justify a premium.

  3. Governance and balance-sheet overhangs persist. Founder control comes with pledges and personal guarantees, cash covered only a third of current liabilities, and the FY2023 impairment history and capitalised R&D (64% in FY2021) leave further write-down risk.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
Q3 2026 report (revenue trajectory; H2 NP recovery)Late Oct 2026
ACT001 Phase III enrolment completion and topline timing2026–2027
Ryzneuta new-country approvals (4 pending) and EU partner launchesRolling
Acrotech US volumes and 2026 order bookRolling
F-652 aGVHD Phase II first-patient-in; N-3C01 Phase I start2026–2027
Compound Yinhua Jiedu paediatric influenza approval after CDE supplements2026–2027
NRDL renewal and price outcomes (Ryzneuta, Hyruan ONE)Late 2026
Vitamin B5 price trendMonthly
Controlling-shareholder pledge ratioRolling
FY2026 dividend and Quality and Return Dual Improvement executionApr 2027

Analyst verdict

Yifan Pharmaceutical is a company whose strategic narrative has outrun its income statement. The narrative itself is credible.

Few Chinese mid-caps have taken a self-developed biologic through FDA, EMA and NMPA approval, won NCCN Category 1 guideline status, and secured a US price roughly fourteen times the domestic one. Ryzneuta's shipment growth (more than 80% in 2025 and more than 50% in H1 2026) and its expanding registration map show the asset is real.

The ACT001 in-licence is a capital-efficient bet on a late-stage, breakthrough-designated oncology asset. Hyruan ONE adds a fast-growing orthopaedic leg.

The reported numbers are less convincing:

  • Five-year revenue CAGR is under 4%.

  • ROE has not exceeded 5% since 2020.

  • Profit has missed consensus repeatedly.

  • H1 2026 attributable NP fell by a third.

The domestic generics and TCM base, still about three-quarters of revenue, faces structural policy pressure. Innovative-product revenue is not yet large enough to offset that pressure, particularly after the NRDL price reset on Ryzneuta. Vitamin B5 adds cyclical noise. Governance features also warrant a discount: concentrated founder control, share pledges and reliance on the chairman's personal guarantees.

At about 35x trailing earnings and 1.4x book, near the bottom of its own valuation history, the market is already pricing considerable scepticism.

The verdict is a qualified, catalyst-dependent positive (Hold with upside bias). Upgrading conviction requires evidence on three fronts:

  1. Q3/Q4 2026 results showing the H2 profit recovery that sell-side estimates assume.

  2. A clean ACT001 Phase III readout path.

  3. Disclosure showing overseas Ryzneuta turning profitable at the segment level.

Failure on the first would argue that the domestic erosion is structural and that the multiple should compress further. Success on all three would support re-rating toward sector multiples.


DATA GAPS & DISCREPANCIES LOG

Entity mismatch: no exact "Jiangsu Yifan Biotechnology Co., Ltd." was found; the dossier profiles Yifan Pharmaceutical (002019.SZ). CB Insights' "based in Jiangsu" conflicts with the company's Zhejiang registration and Anhui operations.

FY2025 consolidated net profit: Pharnexcloud gives RMB 373.45M; cfi.cn gives RMB 431.75M. RMB 373.45M was adopted because it reconciles with RMB 402.02M attributable less RMB 28.57M minorities.

cfi.cn paid-in capital: of RMB 1,036.68M conflicts with the 1,216.39M-share dividend base and EPS; the latter was adopted.

FY2023 own-product revenue: RMB 2,010M (Guosheng, likely domestic only) versus RMB 2,432M (Lixinger, including overseas).

  • Not captured or not publicly disclosed in the sources reviewed:

    • EBITDA and D&A, capex, FCF, interest-bearing debt split, net debt and working capital;

    • domestic/overseas revenue tables, full top-10 shareholders and executive compensation;

    • ISIN, auditor fee and employee trend;

    • FY2022–FY2024 R&D totals;

    • competitor benchmark figures and end-market sizes.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleNotes

Cheng Xianfeng (程先锋)

Chairman, legal representative, controlling shareholder and actual controller; also holds a senior management role

Founder of the Hefei Yifan business; personally guarantees up to RMB 3.0bn of company bank debt at no fee

Feng Deqi (冯德崎)

Director; board secretary; senior executive

Investor-relations and governance lead

Zhou Benyu (周本余)

Director

A related natural person of Cheng Xianfeng (recused on related-party items)

Zeng Yuhong (曾玉红)

Independent director

—

Liu Meijuan (刘梅娟)

Independent director

—

Sixth director

Not identified in the sources reviewed

—

Executive Leadership Team

NameTitleNotes

Cheng Xianfeng

Chairman (and executive)

—

Zhang Dawei (张大巍)

Head of accounting (CFO-equivalent, 主管会计工作负责人)

In role since at least FY2023

Wang Kai (王恺)

Head of accounting department

—

Feng Deqi

Board secretary

—

Simon Li, M.D., Ph.D.

CEO and CMO, Evive Biotech (as of Nov 2022)

—

Yu Haixia (喻海霞)

Former head of accounting (FY2021–FY2022)

Succeeded by Zhang Dawei

Major Shareholders

HolderStakeSource / date

Cheng Xianfeng

Largest holder. 10.06% of floating shares at end-2021; total stake not captured.

CS.com.cn (FY2021)

Hong Kong Securities Clearing (Northbound)

28.68M shares (about 2.36% of total)

Q1 2026 top-10 floating holders

China Innovative Drug ETF (159992)

11.10M shares

Q1 2026

Northbound holding value

RMB 216M, 2.74% of float

Lixinger, 30 Jun 2026

Shareholder accounts

About 46,600 (Jun 2026)

Sina Finance

Share pledges

Pledged shares equal 12.32% of top-10 holdings (Jul 2026); controlling-shareholder pledges extended Feb 2026

Lixinger; Q1 2026 report

Competitive Landscape

Competitors by Segment

SegmentCompetitorProductRelative positioning

Long-acting G-CSF (China)

Jiangsu Hengrui Medicine

Pegfilgrastim (艾多), mecapegfilgrastim

Market leaders with scale advantage; Ryzneuta differentiates on non-PEG design and head-to-head data

Long-acting G-CSF (China)

CSPC Pharmaceutical

PEG-rhG-CSF (津优力)

Incumbent first mover

Long-acting G-CSF (China)

Qilu Pharmaceutical

Pegfilgrastim

Low-cost competitor

Long-acting G-CSF (US)

Amgen

Neulasta® / Onpro

Originator; dominant

Long-acting G-CSF (US)

Coherus BioSciences, Sandoz, Fresenius Kabi, Biocon/Viatris

Pegfilgrastim biosimilars

Price pressure on US end-prices

Long-acting G-CSF (US)

Assertio (formerly Spectrum)

Rolvedon® (eflapegrastim)

Novel competitor and closest analogue

HA viscosupplement (China)

Sanofi (Synvisc-One); Bloomage; domestic HA makers

Single-injection or multi-dose HA

Hyruan ONE competes on the single-injection, six-month profile

Haemato-oncology / APL

Arsenic trioxide producers

ATO injections

Compound Huangdai is the oral alternative

Paediatric / respiratory TCM

Yiling Pharmaceutical; China Resources Sanjiu; Jiangsu Kanion

Respiratory TCM

Category under policy pressure

Vitamin B5

DSM-Firmenich; Brother Enterprise (兄弟科技); Shandong Xinfa (新发药业); Huaheng Biotech (HMO / amino acids)

D-Ca pantothenate

Yifan claims leading global share; commodity pricing

Specialty injectables export

Zhejiang Huahai, Hainan Poly, Nanjing King-friend

EU/US injectables

Overlaps with the international generics platform

Competitor Detail

MetricYifan Pharmaceutical

Revenue

5,133

Revenue growth (%)

-0.5

Gross margin (%)

46.9

Attributable net margin (%)

7.8

R&D intensity (%)

6.9

Recent Developments

--

Company Snapshot

$713.9M

Revenue

4,098

Employees

2000

Founded

SWOT Analysis

Strengths

  • Global regulatory validation. Ryzneuta is approved in 39 countries or regions including China, the US (Nov 2023) and the EU (Mar 2024), and is in NCCN HGF guidelines as Category 1 (v3.2026). Sources: Tianfeng H1 2026; FY2025 annual report.
  • Premium international pricing. The US end-price of USD 4,600 per vial is about 14x China, supported by Acrotech's binding orders above 40k vials in H2 2025. Sources: ifeng; CLS.
  • Mix shift to high-margin own products. Own products rose from 36.9% of revenue (FY2021) to 74.75% (FY2025) at a 51.9% gross margin. Sources: CS.com.cn; Lixinger.
  • Exclusive TCM franchise. 108 approval numbers, 14 exclusive NRDL products, and a WHO-EML-listed product (Compound Huangdai). Source: FY2025 annual report abstract.
  • Global vitamin B5 leadership. About 70% exported with a leading share. Source: FY2025 annual report.
  • Improving earnings quality and cash generation. FY2025 NP excluding non-recurring items +30.9%; H1 2026 OCF RMB 594M, more than double the prior year. Sources: FY2025 annual report; cfi.cn.
  • International GMP footprint. Lines approved by US/EU/Brazil/Singapore/Saudi Arabia regulators; PIC/S inspection; Hefei Xinzhu EU QP-audited. Source: FY2025 annual report.

Weaknesses

  • Earnings volatility. Attributable NP of RMB 968M (2020), 278M (2021), 191M (2022), -551M (2023), 386M (2024) and 402M (2025). Source: annual reports.
  • Low returns. ROE of 2.2–4.6% outside the loss year (FY2021–FY2025). Source: annual reports.
  • Reliance on government grants. The FY2025 gap between attributable and core profit was about RMB 77M, and the Q1 2026 NP drop of 30% was attributed to lower grants. Sources: FY2025 annual report; Q1 2026 report.
  • Ryzneuta still sub-scale overseas. Management admits overseas commercialisation "has not contributed profit at scale". Source: FY2025 annual report abstract.
  • Thin liquidity cover. Cash was 33.6% of current liabilities at 3Q25, and the controlling shareholder guarantees up to RMB 3.0bn of debt. Sources: Stockstar; board resolution 2026-015.
  • Execution slip. The US launch was delayed about 10 months by packaging and supply-chain issues. Source: Gelonghui, Jun 2025.
  • Minority leakage. Evive is only 66.92% owned, so biologics profits are shared and losses partly absorbed by minorities. Source: FY2024 annual report.

Opportunities

  • ACT001. A potential first-in-indication drug for SCLC brain metastases with BTD; Phase III 76% enrolled. Source: Tianfeng.
  • Ryzneuta geographic expansion. Four pending filings and new partners in France, Italy, Poland and Bangladesh. Source: Zheshang note, Sep 2026.
  • Hyruan ONE scale-up. Sales +225% in 2025; positioned as a possible RMB 2bn product (analyst view). Sources: ifeng; Guosheng.
  • F-652 (IL-22) in aGVHD and ACLF. First-in-class optionality. Source: FY2025 annual report.
  • Synthetic biology (HMOs). Regulatory clearance achieved; new Hangzhou plant. Source: investor-relations minutes, 2025.
  • Vitamin-cycle recovery. Management expects capacity exits and consolidation. Source: FY2025 annual report.
  • ASEAN and emerging-market export of TCM and injectables. Four TCMs exported to Singapore; Singapore approval for norepinephrine. Sources: ifeng; Q1 2026 report.

Threats

  • Domestic policy. VBP normalisation and DRG/DIP drove the -7.7% decline in own products in H1 2026. Source: Tianfeng.
  • NRDL price cuts on Ryzneuta. Cited in H1 2026. Source: Tianfeng.
  • US G-CSF competition. Biosimilar pegfilgrastims and Rolvedon (industry structure).
  • Vitamin B5 oversupply. Vitamin revenue fell about 15% in FY2025. Source: Lixinger.
  • FX volatility. FX losses contributed to the H1 2026 profit decline. Source: Tianfeng.
  • Geopolitical and trade risk. "International trade risk" is a named risk factor since FY2024, relevant to US-China tariff and biotech policy. Source: H1 2025 report.
  • Goodwill and asset impairment risk. Demonstrated by the FY2023 loss. Source: FY2023 annual report.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
24 Apr 2025FY2024 annual report: revenue RMB 5,160M (+26.8%), attributable NP RMB 386M; RMB 0.10 final dividendConfirms the turnaround
30 Apr 2025Q1 2025: revenue RMB 1,327M (flat); attributable NP RMB 153M (+4.8%); excluding non-recurring items -13.6%Underlying softness
May 2025Acrotech raises agreed US purchase volumes and sales targets; binding orders above 40k vials (half-year)US demand signal
Late May 2025First Ryzneuta shipment from Germany to the US after about 10 months of delaySupply-chain execution risk materialised, then resolved
2 Jun 2025Investor call: more than 270k vials shipped in China in 2024; terminal net sales above RMB 500MQuantifies the domestic franchise
Jul 2025US commercial sales begin at USD 4,600 per vialPricing power abroad
H1 2025HMO 2'-FL FDA and 6'-SL self-GRAS; amikacin shipped to the EU; norepinephrine PIC/SDiversification and international quality
H1 2025Cytarabine and epirubicin injections approvedHaemato-oncology breadth
14 Aug 2025H1 2025: revenue RMB 2,635M; attributable NP RMB 304M (+19.9%); innovative-drug revenue +169.6%; Hyruan ONE shipments +478%Mix upgrade
31 Oct 20253Q25: 9M revenue RMB 3,923M (+1.7%); Q3 attributable NP RMB 84M (-25.6%)Momentum slowing
2025F-652 higher-dose PK started; N-3C01 IND; insulin glargine and hGH CTAsPipeline breadth
2025Duanjin Jiedu Phase Ib completed; Yinhua Jiedu Phase III completed and filedTCM innovation
2025Ryzneuta included in NCCN v1.2025 and the CSCO breast cancer guideline 2025; AACR and SGO 2025 postersClinical credibility
6 Jan 2026ACT001 exclusive licence (RMB 100M upfront)Late-stage asset addition
6 Jan 2026F-652 China Phase II IND for GVHDPipeline advance
7 Jan / 3 Feb 2026Vitamin K1 injection approvals (two strengths)Portfolio
8 Jan 2026Yihuang decoction granules NDA acceptedTCM classic formula
24 Jan 2026Polymyxin B for injection approvedHospital anti-infective
7 Feb 2026Norepinephrine concentrate approved in SingaporeASEAN expansion
13 Feb 2026Controlling shareholder extends a share pledgeGovernance monitorable
27 Feb 2026Suzhou Yifan and Evive Beijing renew high-tech-enterprise status (15% CIT rate)Tax
22–24 Apr 2026FY2025 results: revenue RMB 5,133M (-0.5%); attributable NP RMB 402M (+4.2%); NP excluding non-recurring items +30.9%; RMB 0.10 dividend (30.26% payout). Auditor re-appointed. RMB 6.5bn credit lines; RMB 3.0bn personal guarantee by the chairman. Quality and Return Dual Improvement plan.Results and governance
24 Apr 2026Q1 2026: revenue RMB 1,256M (-5.4%); attributable NP RMB 107M (-30.3%) on lower grants; OCF +56%Weak start
H1 2026Ryzneuta approved in Albania, Kosovo and Montenegro (39 in total); filed in 4 more; partnerships in France, Italy, Poland and BangladeshGlobal roll-out
H1 2026EMA approves a new overseas formulation site; shelf-life extended to 48 months (EU/FDA)Supply resilience
Aug 2026H1 2026: revenue RMB 2,468M (-6.4%); attributable NP RMB 205M (-32.5%); Ryzneuta + Hyruan ONE shipments +40%, revenue +12.5% despite the NRDL price cutMixed
Sep 2026Tianfeng (Buy, maintained) cuts its FY2026–28 revenue forecasts; Zheshang upgrades to BuySell-side sentiment
11–12 Sep 2026RMB 100M LP commitment to the Gaorong fundCapital allocation

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment (FY2021–FY2025): Total pharma business rose from CNY 4,260 Mn in FY2024 to CNY 4,358 Mn in FY2025.
Jiangsu Yifan Biotechnology Co., Ltd. — Revenue by Segment (FY2021–FY2025)
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Total pharma business———4,2604,358
Pharma own products incl. imported1,627—2,4323,6643,837
Vitamins B5 series470——718613
API segment total, incl. vitamins1,062————
Pharma promotion services907————
Group revenue4,4093,8374,0685,1605,133

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. FY2025 Annual Report Abstract, Board Resolutions (2026-015 to 2026-018) and Q1 2026 Report, Shanghai Securities News (24 Apr 2026) (paper.cnstock.com)
  2. FY2024 Annual Report (key data, glossary, company info), Pharnexcloud (pharnexcloud.com)
  3. FY2025 Annual Report summary, Pharnexcloud (pharnexcloud.com)
  4. FY2023 Annual Report summary, Pharnexcloud (pharnexcloud.com)
  5. FY2022 Annual Report summary, Pharnexcloud (pharnexcloud.com)
  6. Q1 2025 Report, Pharnexcloud (pharnexcloud.com)
  7. Financial indicators H1 2026 / FY2025, cfi.cn: and: quote.cfi.cn · quote.cfi.cn
  8. FY2021 results coverage, China Securities Journal (cs.com.cn)
  9. Guojin FY2021 note and Guosheng FY2023 note, Pharnexcloud Consult (consult.pharnexcloud.com)
  10. FY2025 results feature, Investor Network / ifeng (24 Apr 2026) (i.ifeng.com)
  11. Tianfeng H1 2026 note, Gelonghui (m.gelonghui.com)
  12. Zheshang note coverage, Caiwen (10 Sep 2026) (caiwennews.com)
  13. Gaorong fund announcement (2026-058/059): and: i.ifeng.com · wap.stockstar.com
  14. H1 2025 results, CLS · DoNews
  15. H1 2025 report abstract, Shanghai Securities News (paper.cnstock.com)
  16. 3Q25 results and consensus, Stockstar (stock.stockstar.com)
  17. FY2023 results, Stockstar (stock.stockstar.com)
  18. H1 2024 results, STCN (stcn.com)
  19. H1 2024 profit pre-announcement, CNINFO (static.cninfo.com.cn)
  20. Ryzneuta 2024 sales and US launch, Gelonghui (3 Jun 2025) (m.gelonghui.com)
  21. Investor-relations minutes (H1 2025), Fxbaogao (fxbaogao.com)
  22. 2017 private placement / capital injection, SZSE (disc.static.szse.cn)
  23. FY2021 profit warning, SZSE (disc.static.szse.cn)
  24. Acrotech license press release, Aurobindo NSE filing (23 Nov 2022) (archives.nseindia.com)
  25. Market data / valuation, Lixinger (lixinger.com)
  26. Shareholder and dividend data, Sina Finance (22 Jun 2026) (finance.sina.cn)
  27. Polymer / PBS capacity, Sina Finance (29 May 2026) (finance.sina.cn)
  28. Company profile (address, employees), Morningstar (morningstar.com.au)
  29. Company profile, CB Insights (cbinsights.com)
  30. Business description, GlobalData (globaldata.com)
  31. ESG scores, KnowESG (knowesg.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.